See more : Herc Holdings Inc. (0J4L.L) Income Statement Analysis – Financial Results
Complete financial analysis of RVL Pharmaceuticals plc (OSMT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RVL Pharmaceuticals plc, a leading company in the Biotechnology industry within the Healthcare sector.
- ARSS Infrastructure Projects Limited (ARSSINFRA.NS) Income Statement Analysis – Financial Results
- Sagittarius Life Science Corp (3205.TWO) Income Statement Analysis – Financial Results
- FTAC Parnassus Acquisition Corp. (FTPAW) Income Statement Analysis – Financial Results
- QANTM Intellectual Property Limited (QIP.AX) Income Statement Analysis – Financial Results
- Adverum Biotechnologies, Inc. (ADVM) Income Statement Analysis – Financial Results
RVL Pharmaceuticals plc (OSMT)
About RVL Pharmaceuticals plc
Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company's promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson's disease and drug-induced extrapyramidal reactions in adults; Arbaclofen extended-release tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity; Upneeq, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis; and OS870 which is in Phase I clinical trial for the treatment of neurodegenerative disorders. It also provides women's health products, including Divigel for menopause; and OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods. In addition, the company's non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorders and social anxiety disorders; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; prescription prenatal vitamins for treating nutritional requirements during pregnancy; Lorzone, an immediate-release form of chlorzoxazone indicated for the treatment of acute musculoskeletal pain in conjunction with rest and physical therapy; ConZip, a tramadol hydrochloride for the management of pain; and nitrofurantoin for the treatment of urinary tract infections, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 49.72M | 17.50M | 27.76M | 240.03M | 263.70M | 245.75M | 218.46M |
| Cost of Revenue | 9.46M | 3.62M | 3.29M | 111.63M | 140.08M | 125.19M | 125.62M |
| Gross Profit | 40.27M | 13.88M | 24.47M | 128.40M | 123.62M | 120.56M | 92.84M |
| Gross Profit Ratio | 80.98% | 79.33% | 88.14% | 53.49% | 46.88% | 49.06% | 42.50% |
| Research & Development | 3.97M | 6.93M | 13.39M | 32.32M | 43.69M | 42.69M | 29.06M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 81.98M | 87.46M | 72.82M | 93.03M | 74.24M | 56.95M | 65.96M |
| Other Expenses | 6.26M | -1.33M | -48.00K | 884.00K | 664.39K | -4.52M | 168.73K |
| Operating Expenses | 85.95M | 94.39M | 86.21M | 125.35M | 117.94M | 99.64M | 95.02M |
| Cost & Expenses | 95.40M | 98.01M | 89.50M | 236.98M | 258.02M | 224.83M | 220.64M |
| Interest Income | 2.86M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.11M | 4.02M | 4.10M | 18.21M | 20.79M | 29.05M | 20.19M |
| Depreciation & Amortization | 9.49M | 6.84M | 20.98M | 57.02M | 81.57M | 46.45M | 23.59M |
| EBITDA | -36.19M | -73.67M | -40.76M | 60.95M | -664.39M | 62.85M | 21.58M |
| EBITDA Ratio | -72.78% | -420.94% | -146.83% | 25.39% | 33.34% | 25.57% | 9.88% |
| Operating Income | -45.68M | -80.51M | -61.74M | 3.94M | -98.54M | -52.07M | -32.05M |
| Operating Income Ratio | -91.87% | -460.03% | -222.40% | 1.64% | -37.37% | -21.19% | -14.67% |
| Total Other Income/Expenses | -6.03M | 315.00K | -33.05M | -301.96M | -20.13M | -33.57M | -20.02M |
| Income Before Tax | -51.71M | -82.53M | -94.80M | -298.02M | -118.66M | -85.64M | -52.07M |
| Income Before Tax Ratio | -104.00% | -471.60% | -341.46% | -124.16% | -45.00% | -34.85% | -23.83% |
| Income Tax Expense | -20.00K | 315.00K | -5.78M | -27.12M | -8.98M | -40.49M | -10.25M |
| Net Income | -51.69M | -82.85M | -89.01M | -270.90M | -109.68M | -45.15M | -41.82M |
| Net Income Ratio | -103.96% | -473.40% | -320.63% | -112.86% | -41.59% | -18.37% | -19.14% |
| EPS | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -1.05 | -0.98 |
| EPS Diluted | -0.58 | -1.23 | -1.47 | -5.17 | -2.42 | -0.98 | -0.98 |
| Weighted Avg Shares Out | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 42.86M | 42.85M |
| Weighted Avg Shares Out (Dil) | 89.80M | 67.35M | 60.65M | 52.37M | 45.28M | 45.86M | 42.85M |
Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021
Analysts Estimate OSMOTICA PHARM (OSMT) to Report a Decline in Earnings: What to Look Out for
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Osmotica Pharmaceuticals plc - OSMT
Osmotica Pharmaceuticals plc (OSMT) CEO Brian Markison on Q4 2020 Results - Earnings Call Transcript
Osmotica Pharmaceuticals: Q4 Earnings Insights
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021
Source: https://incomestatements.info
Category: Stock Reports